In Vivo Emergence of Dual Resistance to Rifampin and Levofloxacin in Osteoarticular Cutibacterium avidum

In this study, we report for the first time the in vivo emergence of dual resistance to levofloxacin and rifampin in C. avidum isolated from a patient who received both antibiotics orally in the setting of a salvage debridement and implant retention of an ODRI. Aside from the molecular insights reported here, this study highlights potential limitations of the combination of oral rifampin and levofloxacin in patients undergoing these surgical procedures and the potential need to evaluate specific optimal therapy for emerging ODRI pathogens. ABSTRACT Cutibacterium avidum is an emerging causative agent of orthopedic device-related infections (ODRIs). There are no guidelines for the antimicrobial treatment of C. avidum ODRI, but oral rifampin is frequently used in combination with a fluoroquinolone following intravenous antibiotics. We describe the in vivo emergence of combined resistance to rifampin and levofloxacin in a C. avidum strain isolated from a patient with early-onset ODRI treated with debridement, antibiotic treatment, and implant retention (DAIR) using rifampin combined with levofloxacin as the oral treatment. Whole-genome sequencing of C. avidum isolates before and after antibiotic exposure confirmed strain identity and identified new mutations in rpoB and gyrA, leading to amino acid substitutions previously reported to be associated with resistance to rifampin (S446P) and fluoroquinolones (S101L), respectively, in other microbial agents, in the posttherapy isolate. Aside from the molecular insights reported here, this study highlights potential limitations of the combination of oral rifampin and levofloxacin in patients undergoing a DAIR procedure for C. avidum ODRI and the potential need to evaluate specific optimal therapy for emerging ODRI pathogens. IMPORTANCE In this study, we report for the first time the in vivo emergence of dual resistance to levofloxacin and rifampin in C. avidum isolated from a patient who received both antibiotics orally in the setting of a salvage debridement and implant retention of an ODRI. Aside from the molecular insights reported here, this study highlights potential limitations of the combination of oral rifampin and levofloxacin in patients undergoing these surgical procedures and the potential need to evaluate specific optimal therapy for emerging ODRI pathogens.

[1]  J. Pawlotsky,et al.  Pathogen identification by shotgun metagenomics of patients with necrotizing soft‐tissue infections , 2020, The British journal of dermatology.

[2]  M. Broly,et al.  Propionibacterium/Cutibacterium species–related positive samples, identification, clinical and resistance features: a 10-year survey in a French hospital , 2020, European Journal of Clinical Microbiology & Infectious Diseases.

[3]  B. Heym,et al.  Cutibacterium (Formerly Propionibacterium) avidum: A Rare but Avid Agent of Prosthetic Hip Infection. , 2018, The Journal of arthroplasty.

[4]  S. Corvec.  Clinical and Biological Features of Cutibacterium (Formerly Propionibacterium) avidum, an Underrecognized Microorganism , 2018, Clinical Microbiology Reviews.

[5]  R. Sutter,et al.  Propionibacterium avidum: A Virulent Pathogen Causing Hip Periprosthetic Joint Infection , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  F. Pecorari,et al.  In vitro emergence of fluoroquinolone resistance in Cutibacterium (formerly Propionibacterium) acnes and molecular characterization of mutations in the gyrA gene. , 2017, Anaerobe.

[7]  John P. Didion,et al.  Atropos: specific, sensitive, and speedy trimming of sequencing reads , 2017, PeerJ.

[8]  H. Nakaminami,et al.  Emergence of fluoroquinolone-resistant Propionibacterium acnes caused by amino acid substitutions of DNA gyrase but not DNA topoisomerase IV. , 2016, Anaerobe.

[9]  Rida Assaf,et al.  Improvements to PATRIC, the all-bacterial Bioinformatics Database and Analysis Resource Center , 2016, Nucleic Acids Res..

[10]  B. Söderquist,et al.  Propionibacterium avidum as an Etiological Agent of Prosthetic Hip Joint Infection , 2016, PloS one.

[11]  A. Wong,et al.  The fitness costs of antibiotic resistance mutations , 2014, Evolutionary applications.

[12]  Alexey A. Gurevich,et al.  QUAST: quality assessment tool for genome assemblies , 2013, Bioinform..

[13]  Jens Stoye,et al.  Updating benchtop sequencing performance comparison , 2013, Nature Biotechnology.

[14]  A. Trampuz,et al.  In vitro emergence of rifampicin resistance in Propionibacterium acnes and molecular characterization of mutations in the rpoB gene. , 2013, The Journal of antimicrobial chemotherapy.

[15]  J. Gaillard,et al.  Diagnosis of prosthetic joint infection by beadmill processing of a periprosthetic specimen. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  D. Hooper,et al.  Impact of Ciprofloxacin Exposure on Staphylococcus aureus Genomic Alterations Linked with Emergence of Rifampin Resistance , 2011, Antimicrobial Agents and Chemotherapy.

[17]  Arkady Mustaev,et al.  Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase , 2001, Cell.

[18]  Kenichi Sato,et al.  Detection of grlA and gyrA Mutations in 344 Staphylococcus aureus Strains , 1998, Antimicrobial Agents and Chemotherapy.

[19]  L. Peterson,et al.  DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli , 1990, Journal of bacteriology.

[20]  T J O'Donnell,et al.  Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model. , 1989, Biochemistry.